GlassScriptPhysician profile
Shilpa Vaidya
NPI 1730105560
$6,253.43
in general payments reported to CMS, 2019-2025
41 companies · $1,614 in 2025
The $1,614 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $600 · 2020: $280 · 2021: $400 · 2022: $487 · 2023: $1,190 · 2024: $1,682 · 2025: $1,614.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,486.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,485.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,695.60 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $1,176.27 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $648.13 | 2019-2025 | |
| Abbott Laboratories | $399.63 | 2021-2025 | Freestyle Libre 3, Proclaim, Octrode |
| Astellas Pharma US INC | $279.74 | 2019-2025 | Veozah, Myrbetriq |
| Lilly USA, LLC | $204.28 | 2019-2025 | Zepbound, Mounjaro |
| Glaxosmithkline, LLC. | $189.38 | 2023-2025 | Shingrix, Arexvy |
| Amgen INC. | $181.90 | 2019-2025 | Otezla, Repatha, Repatha |
| Dexcom, INC. | $166.52 | 2023-2025 | Dexcom G6 Transmitter |
| Axsome Therapeutics, INC. | $130.62 | 2023-2025 | Auvelity, Sunosi |
| Allergan, INC. | $129.73 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $109.34 | 2019-2024 | Breztri, Airsupra |
| Esperion Therapeutics, INC. | $66.95 | 2024-2025 | Nexletol |
| Inspire Medical Systems, INC. | $62.27 | 2024-2025 | Inspire |
| Jazz Pharmaceuticals INC. | $59.01 | 2021-2022 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shilpa Vaidya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.